{"id":"dbpr108-placebo-matching-sitagliptin","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1201174","moleculeType":"Small molecule","molecularWeight":"523.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo control formulation matched to sitagliptin, DBPR108 itself is inert but designed to be indistinguishable from active sitagliptin in clinical trials. Sitagliptin works by inhibiting DPP-4, an enzyme that degrades glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By preserving these incretin hormones, sitagliptin enhances glucose-dependent insulin secretion and reduces glucagon secretion, thereby lowering blood glucose levels in type 2 diabetes patients.","oneSentence":"DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:37.825Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Placebo control for type 2 diabetes mellitus trials"}]},"trialDetails":[{"nctId":"NCT04161430","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2020-01-02","conditions":"Type 2 Diabetes Mellitus","enrollment":766}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"DBPR108; Placebo matching sitagliptin","genericName":"DBPR108; Placebo matching sitagliptin","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DBPR108 is a placebo matching formulation designed to match sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels to stimulate insulin secretion in response to glucose. Used for Placebo control for type 2 diabetes mellitus trials.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}